Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial - PubMed
3 days ago
- #septic shock
- #albumin therapy
- #clinical trial
- Albumin replacement therapy was tested in a randomized clinical trial for septic shock patients.
- The study aimed to assess the impact of albumin administration on patient outcomes.
- Conducted across 23 intensive care units in Germany from 2019 to 2022.
- Patients received either 20% albumin or standard crystalloid fluids.
- Primary endpoint was 90-day mortality, with no significant difference between groups (43.3% vs 45.9%).
- Secondary endpoints also showed no significant differences.
- The trial was terminated early due to low enrollment, making results inconclusive.
- Albumin administration was found to be safe but did not improve survival rates.
- Additional studies are recommended to further evaluate the therapy's efficacy.